Scotiabank analyst Louise Chen lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $9 from $15 and keeps an Outperform rating on the shares. The firm is lowering its price target on the stock due to lower sales for bosakitug, the analyst tells investors. The firm, however, continues to believe pipeline advancements and commercialization, as well as potential partnerships, will drive upwards earnings revisions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics Reports Q1 2025 Financial Results
- Aclaris Therapeutics reports Q1 EPS (12c), consensus (12c)
- Aclaris Therapeutics appoints Hall as Chief Medical Officer
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
- Aclaris Therapeutics’ IND for ATI-052 candidate granted FDA clearance